ArticleScientific reports2025
A novel radiosensitizer α-sulfoquinovosyl-acylpropanediol (SQAP) inhibits DNA repair pathways and sensitize cells to cancer chemotherapeutic agents.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Sulfoglycolipid, α-sulfoquinovosyl-acylpropanediol (SQAP) is a novel veterinary radiosensitizer, which is known to cause angiogenesis alteration and sensitizes hypoxic tumors in the in vivo animal model. We examined the SQAP radio/chemo-sensitization mechanisms from DNA repair with canine cancer cell lines and Chinese hamster cell lines. Previous studies have shown that SQAP radiosensitization was limited to in vivo xenograft models, but we found SQAP sensitized cells to radiation in vitro cell culture system. SQAP sensitized canine osteosarcoma and melanoma cell lines to gamma-ray irradiation in normoxia or hypoxia conditions. This result suggested that SQAP was expected to affect the repair of DNA damage induced by ionizing radiation and enhanced cellular radiosensitivity. To further identify potential mechanisms of radiosensitization, we utilized several assays to determine DNA repair inhibition by SQAP. SQAP treatment inhibited NHEJ and HR activity measured by EJ5-GFP and DR-GFP assays. SQAP treatment reduced the spontaneous sister chromatid exchange formation in CHO wild type and EM9 (XRCC1 mutant). On the other hand, 51D1 (rad51d mutant, homologous recombination (HR) repair deficient) showed no reduction. In vitro topoisomerase assay revealed SQAP disrupted topoisomerase I and II alpha activities. SQAP sensitized series of chemotherapeutic agents including doxorubicin, carboplatin, bleomycin, camptothecin, etoposide, methyl methanesulfonate, cisplatin, mitomycin C, and Taxol in canine tumor cells and V79 cells. These results suggest that broad inhibition of DNA repair may play a role in SQAP induced radiosensitization and chemosensitization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.